Journal Article

New β-Lactamases in Gram-Negative Bacteria: Diversity and Impact on the Selection of Antimicrobial Therapy

George M. Eliopoulos and Karen Bush

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 32, issue 7, pages 1085-1089
Published in print April 2001 | ISSN: 1058-4838
Published online April 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/319610
New β-Lactamases in Gram-Negative Bacteria: Diversity and Impact on the Selection of Antimicrobial Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Of the 340 discrete β-lactamases that have been identified, the most important groups of enzymes that are continuing to proliferate include the plasmid-encoded cephalosporinases, the metallo-β-lactamases, and the extended-spectrum β-lactamases. Resistance to specific β-lactam-containing antimicrobial agents frequently can be traced to a single β-lactamase, but this task is becoming more difficult for the clinical microbiology laboratory. Other factors, such as multiple β-lactamase production, transferable multidrug-resistance genes, alterations in outer-membrane porins, and possible antibiotic efflux, all may contribute to a resistance phenotype. Appreciation of these factors may help the physician make a more informed decision when choosing therapy to try to avoid selection of even more pathogenic strains.

Journal Article.  3513 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.